January 21, 2022

Announcements

Genomics, Genetics, & Epigenetics Research Program Leadership

We are pleased to announce that Jeffrey Townsend, PhD, and Qin Yan, PhD, join Lajos Pusztai, MD, DPhil, as Co-Leaders of the Genomics, Genetics, & Epigenetics (GGE) Research Program. Dr. Townsend is the Elihu Professor of Biostatistics and Professor of Ecology and Evolutionary Biology. His research focuses on modeling evolutionary genomics and uses computational analyses to determine which genes are essential to the evolution of cancer. Dr. Yan is an Associate Professor of Pathology and Director of the Center for Epigenetics and Biomarkers, Pathology. His laboratory is focused on understanding the epigenetic mechanisms that drive tumor initiation and progression, particularly in breast cancer tumors, and has made significant contributions to the understanding of KDM5 H3K4me3/2 histone demethylases. Together, Drs. Pusztai, Townsend, and Yan will drive the study of gene alterations in cancer forward, together with the entire membership of our GGE Research Program.

Julie Jung Kang, MD, PhD, Appointed to Therapeutic Radiology

We are pleased to welcome Julie Jung Kang, MD, PhD to the...
Julie Jung Kang, MD, PhD, joins the Department of Therapeutic Radiology. Dr. Kang will join the Smilow Radiation Oncology team in Trumbull in April from Memorial Sloan Kettering Cancer Center (MSKCC), where she is currently an Assistant Attending of Radiation Oncology.

Dr. Kang is a graduate of Yale University. She received her medical degree in 2010 from Keck School of Medicine of USC where she also received her PhD in Systems Biology. At MSKCC, she has led clinical trials in treatment de-escalation and immunotherapy in head and neck cancer. Her clinical and research interests include head and neck cancer and genitourinary malignancies.

Notables

Gilda’s Club Westchester has honored D. Barry Boyd, MD, MS, Assistant Professor of Medicine (Medical Oncology) at the Smilow Cancer Hospital Care Center in Greenwich, with the inaugural Spirit of Excellence in Oncology Award for his incredible contributions to the field of oncology. The Club recognized Dr. Boyd for the care he gave to Gilda Radner and the thousands of patients with cancer over the past 20+ years and for his support of the Gilda’s Club mission through our Professional Advisory Board.

We are proud to announce that four 2021 Young Investigator Award winners were selected by the American Journal of Hematology (AJH) in recognition of their study, “Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis.” George Goshua, MD, Clinical Fellow in the Hematology/Oncology Fellowship Program, Matthew Meizlish, MPhil, a MD/PhD student in the lab of Dr. Ruslan Medzhitov, Rebecca Fine, MD, Resident in Internal Medicine, and Yiwen Liu, MS, of Dana-Farber Cancer Institute, were honored as first authors of the publication based on the scientific quality and originality of the work.

Aileen Fernandez, PhD, a postdoctoral fellow in the laboratory of David Rimm, MD, PhD, in the Department of Pathology, was awarded a travel grant to attend the Society for Immunotherapy of Cancer’s Cancer Immunotherapy Winter School 2022 next week. The award is to support young investigators and clinicians to supplement costs to attend the conference.

Elizabeth Prsic, MD, Assistant Professor of Medicine (Medical Oncology) Breast Surgeon joins Smilow Cancer Hospital Care Center at Greenwich

Read More

How to Better Support a Loved One With Cancer

Read More

Chen Liu, MD, PhD, Leads Effort to Establish Institutional Biorepository at Yale School of Medicine

Read More

Gloria Huang, MD, in Honor of Cervical
Elizabeth Prsic, MD, Assistant Professor of Medicine (Medical Oncology) and Director of the Adult Inpatient Palliative Care Program for Smilow Cancer Hospital, has been named a Panel Member for the Clinical Practice Guidelines on Adult Cancer Pain for the National Comprehensive Cancer Network.

Janie Zhang, MD, a Clinical Fellow in the Hematology/Oncology fellowship program, has received a 2022 ASCO Foundation Conquer Cancer Award in recognition of her abstract at ASCO GI, Clinical Significance and Biomarker Potential of MGMT Protein Measurement in Colorectal Cancer.

Maryam Lustberg, MD, MPH, Associate Professor of Medicine (Medical Oncology) and Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, has co-edited Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy.

Mehra Golshan, MD, MBA, Deputy Chief Medical Officer for Surgical Services and Professor of Surgery (Surgical Oncology), presented on Innovative Image Guided Breast Surgery: Intraoperative MRI, Mass Spec and Beyond at the 14th Breast- Gynecological & Immunooncology International Cancer Conference earlier this week from Cairo, Egypt.

Elena Ratner, MD, Professor of Obstetrics, Gynecology & Reproductive Sciences, and Stanton Honig, MD, Professor of Urology, shared their expertise and presented on Sexuality, Intimacy and Menopause for Cancer Survivors and Fertility in the Oncologic Patient last week during an International CME meeting on Survivorship and Cancer Control: Raising the Goals and Optimizing Care Forum hosted from Riyadh, Saudi Arabia. In addition, Mehra Golshan, MD, MBA, served on the scientific committee for the program, as moderator, and as a presenter on Management of Chronic Symptoms and Complications Post Breast Cancer Surgery.

Gregory Riley has joined Yale Cancer Center as the Division Administrator for Medical Oncology. In this newly created role, Greg will serve as the strategic and operational leader for the Section of Medical Oncology, partnering closely with the Section Chief, Deputy Director, and Associate Director of Finance on development of annual budgets and reports, monitoring clinical revenue performance and productivity metrics, and partnering with Smilow operations leadership on clinical practice management and business plan performance tracking. Greg will work closely with Roy S. Herbst, MD, PhD, Chief of Medical Oncology, and Medical Oncology leadership to lead and support Section initiatives and communications including clinical care, research, education, faculty leadership, and Diversity, Equity, and Inclusion initiatives.

The Yale Cancer Center Genetics, Genomics, & Epigenetics Research Program is proud to welcome Mathieu Bakhoum, MD, PhD, and E. Zeynep Erson Omay, PhD to its program. Dr. Bakhoum is an Assistant Professor of Ophthalmology (Retina) and Dr. Erson Omay is an Assistant Professor of Neurosurgery.
Dr. Bakhoum's current work aims to functionally link two hallmarks of cancer, chromosomal instability, and epigenetic alterations, while explaining how they interact to drive tumor progression, with a special focus on uveal melanoma. The overarching goal of Dr. Bakhoum's independent research program is to determine mechanisms that regulate metastasis-initiation in uveal melanoma and translate this knowledge to develop non-invasive biomarkers for diagnosis and metastatic surveillance, and to identify druggable targets that can be employed to inhibit uveal melanoma progression.

Dr. Erson Omay is a computational biologist specializing in molecular characterization of primary brain tumors utilizing various multi-omic/multi-level methods. She has been leading the efforts in computational multi-omic analysis of various tumor types such as meningiomas, gliomas, and pituitary adenomas. Her recent studies have been focusing on the inter- and intra-tumor genomic heterogeneity and molecular characterization of rare subtypes/clinical outlier groups in various brain tumor types.

The NCCN 2022 Breast Cancer Congress with updates from the 2021 San Antonio Breast Cancer Symposium (SABCS) will be held virtually on Friday, February 11, 2022, from 10:00 AM – 5:30 PM EST. This program will feature NCCN Member Institution experts, including Maryam Lustberg, MD, MPH, Kathryn Daniels Mason, FNP, and Annette Hood, PharmD, BCACP, from Smilow Cancer Hospital presenting on pain and neuropathy, and review the current standard of care for patients with breast cancer, the latest NCCN Guidelines recommendations, and recent clinical research updates. To register for the upcoming Virtual Congress, click here.

Please save the date for the Yale Liver Diamond Jubilee on February 25, 2022 from 8:30 am to 5:15 pm. This event, organized by the Yale Liver Center, will celebrate 75 years of academic hepatology at Yale! During these 75 years, Hepatology became a complex scientific discipline with multiple ramifications in all fields of biomedicine. These efforts have resulted in improved treatments and outcomes for patients affected by liver disease. Hepatology is now a high intensity discipline practiced by physicians with diverse backgrounds and skills. From a platform built on “Yale Liver” accomplishments, we will look at the path ahead and the scientific and clinical questions that will keep the hepatology community occupied for years to come.

Diversity, Equity, and Inclusion

Congratulations to Natalie Smith, MS, RDN, nutrition program coordinator, Smilow Cancer Hospital Care Center at Waterford, who recently received the Lawrence + Memorial Hospital 365 Award, a prestigious honor given to hospital members who best exemplify our mission, vision, and values, with a focus on our patients and each other — 365 days a year!
Yale Panel to Develop Measures to Address Equity in Incidental Lung Nodule Follow-up

CT scanning of the chest is frequently performed in emergency department patients to detect injuries from trauma or conditions such as a pulmonary embolism or aortic pathology. While most of these scans will be negative, as many as 20% may reveal a lung nodule for which follow-up is recommended, and a small number of these will progress to cancer. Early diagnosis of lung cancer is crucial to outcomes.

Unfortunately, many patients may not receive this follow-up, and follow-up may often depend on social determinants of health including insurance status, race/ethnicity, and socioeconomic status. With funding support from the Gordon and Betty Moore Foundation, Yale School of Medicine is creating an Equity in Cancer Diagnosis Technical Expert Panel to provide guidance in the development of equity measures in the follow-up and diagnosis of cancer in emergency department patients.

Learn More

Employee Profile: Dismayra Martinez

For the nearly six years, Dismayra Martinez, MHE, CCRP, has served as a liaison between Principal Investigators, their respective study team, and the various oversight committees in her role as a Research Oversight Committee Regulatory Analyst for the Yale Center for Clinical Investigation. Dismayra is responsible for appropriately coordinating, assigning, and documenting the oversight committees’ review of new and ongoing research within Yale Cancer Center.

Dismayra is also responsible for scheduling meetings, onboarding new committee members, and handling the day-to-day operations required for making sure the oversight committees are running smoothly. Outside of her work life, Dismayra is involved in the Yale Latino Networking Group (YLNG), which she co-chaired for two years. YLNG seeks to promote a community of interest among Latino staff members, and to promote an inclusive and empowering work environment for all Yale employees. She found it very fulfilling to join this group after moving to Connecticut from NYC 11 years ago, and it was a way for her to meet people and get involved in the community.

“I am constantly learning in this role and enjoy being a part of the Yale family,” said Dismayra. “This job is a perfect fit for me as I enjoy working on the research side of things, and there is constantly something new happening in this field.”

Natalie spearheaded a program for our patients who have cancers of the head and neck to ensure that they have not only the nutritional support, but also the emotional and rehabilitative support in order to navigate the side effects from their multiple treatments. Her groundwork in early initiation of feeding tubes has set a new standard for patient care. During this past year, Natalie achieved her Certified Specialist in Oncology Nutrition and is now one of only twenty in the state to achieve this high distinction.

Read More

“Typically we would give patients chemotherapy, but what we’ve learned is if we add some of these newer biological therapies & targeted agents, patients are doing a lot better.” Smilow Cancer Hospital’s Dr. Francine Foss on the evolution in the treatment of T-Cell Lymphoma.
Recent Publications

Patel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmansky J, Johung K, Lacy J
Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System
Read More

Standardizing the Reporting of Incidental, Non-Lung Cancer (Category S) Findings Identified on Lung Cancer Screening Low Dose Computed Tomography
Chest, Online ahead of print.
Read More

Im Y, Huang Y, Huang J, Ma S.
Bayesian Hierarchical Finite Mixture Of Regression For Histopathological Imaging-Based Cancer Data Analysis
Statistics in Medicine, Online ahead of print.
Read More

Sugalski JM, Franco T, Shulman LN, Souza E, Hochberg E, Chiang A, Lawrence S, Krause D, Kubal T.
COVID-19 and Cancer Center Operations: Lessons Learned From the NCCN Best Practices Committee
Journal of the National Comprehensive Cancer Network, Online ahead of print.
Read More

Linderman GC, Zhao J, Roulis M, Bielecki P, Flavell RA, Nadler B, Kluger Y.
Zero-preserving Imputation Of Single-Cell RNA-Seq Data
Read More

Zheng C, Chagpar AB.
Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis
Breast Cancer Research and Treatment, Online ahead of print.
Read More

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)
Journal of Clinical Oncology, Online ahead of print.
Read More

JAN 25
Smilow Shares: Learning about Lung Cancer--Screening and Treatment
Public · Hosted by Smilow Cancer Hospital
TUESDAY, JANUARY 25 | 7:00PM
Learning About Lung Cancer Screening and Treatment
Read More

Tune in to Yale Cancer Answers to hear a discussion with Dr. Amy Justice and Dr. Vin Lo Rey, from the University of Pennsylvania, to learn how they collaborate across institutions to conduct important research into medications that increase the risk of developing liver cancer. Listen on Connecticut Public Radio or download our podcast from iTunes.

January is cervical health awareness month. Our Gynecologic Oncology Program team is available to consult and assist women in need of screening, HPV vaccination, diagnosis, treatment, and supportive care. Please take a moment to learn more about the services available, and reach out if you need assistance.
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer who underwent Adjuvant Osimertinib in the phase III ADAURA Trial

Clinical Cancer Research, Online ahead of print.


[89Zr]ZrDFO-CR011 positron Emission Tomography Correlates With Response To Glycoprotein Non-Metastatic Melanoma B-Targeted Therapy In Triple Negative Breast Cancer

Molecular Cancer Therapeutics, Online ahead of print.

Bewersdorf JP, Prebet T, Gowda L.

Azacitidine Maintenance In AML Post Induction And Posttransplant

Current Opinion in Hematology, Online ahead of print.

Bewersdorf JP, Zeidan AM.

Myeloid-derived Suppressor Cells: A Grey Eminence In The AML Tumor Microenvironment?

Expert Review of Anticancer Therapy, Online ahead of print.


Nature Medicine, Online ahead of print.


The METTL5-TRMT112 N 6-methyladenosine Methyltransferase Complex Regulates mRNA Translation via 18S rRNA Methylation

Journal of Biological Chemistry, Online ahead of print.


Exposure-response Relationship Of Ramucirumab In RANGE, A Randomized Phase III Trial In Advanced Urothelial Carcinoma Refractory To Platinum Therapy

British Journal of Clinical Pharmacology, Online ahead of print.

Thanks to the inspiring leadership of Chief Fellows Dr. Anna Kress & Dr. Benjamin Lu, our Yale Medical Oncology/Hematology Fellowship Program has Diversity, Equity & Inclusion curriculum integrated into the didactic component of training for all fellows.


Nature Medicine, Online ahead of print.


The METTL5-TRMT112 N 6-methyladenosine Methyltransferase Complex Regulates mRNA Translation via 18S rRNA Methylation

Journal of Biological Chemistry, Online ahead of print.


Exposure-response Relationship Of Ramucirumab In RANGE, A Randomized Phase III Trial In Advanced Urothelial Carcinoma Refractory To Platinum Therapy

British Journal of Clinical Pharmacology, Online ahead of print.

Thanks to the inspiring leadership of Chief Fellows Dr. Anna Kress & Dr. Benjamin Lu, our Yale Medical Oncology/Hematology Fellowship Program has Diversity, Equity & Inclusion curriculum integrated into the didactic component of training for all fellows.


Nature Medicine, Online ahead of print.


The METTL5-TRMT112 N 6-methyladenosine Methyltransferase Complex Regulates mRNA Translation via 18S rRNA Methylation

Journal of Biological Chemistry, Online ahead of print.


Exposure-response Relationship Of Ramucirumab In RANGE, A Randomized Phase III Trial In Advanced Urothelial Carcinoma Refractory To Platinum Therapy

British Journal of Clinical Pharmacology, Online ahead of print.

Thanks to the inspiring leadership of Chief Fellows Dr. Anna Kress & Dr. Benjamin Lu, our Yale Medical Oncology/Hematology Fellowship Program has Diversity, Equity & Inclusion curriculum integrated into the didactic component of training for all fellows.


Nature Medicine, Online ahead of print.


The METTL5-TRMT112 N 6-methyladenosine Methyltransferase Complex Regulates mRNA Translation via 18S rRNA Methylation

Journal of Biological Chemistry, Online ahead of print.


Exposure-response Relationship Of Ramucirumab In RANGE, A Randomized Phase III Trial In Advanced Urothelial Carcinoma Refractory To Platinum Therapy

British Journal of Clinical Pharmacology, Online ahead of print.

Thanks to the inspiring leadership of Chief Fellows Dr. Anna Kress & Dr. Benjamin Lu, our Yale Medical Oncology/Hematology Fellowship Program has Diversity, Equity & Inclusion curriculum integrated into the didactic component of training for all fellows.
Funding and Award Opportunities

ASCO Medical Student Rotation for Underrepresented Populations
Provides financial support for U.S. medical students from populations underrepresented in medicine and who are interested in oncology as a career to experience a minimum 4-week clinical or clinical research rotation.

Application Deadline: January 25, 2022
Read More

ASCO Diversity Mentoring Program
Designed to encourage U.S. based medical students and residents who are underrepresented in medicine to pursue rewarding careers in oncology by pairing with a mentor.

Application Deadline: January 25, 2022
Read More

BMSF Clinical Investigator Pipeline Program
This Program was established to build the pipeline of community oriented clinical trialists of diverse backgrounds who are committed to increasing diversity, equity and inclusion in clinical trials. This will be a 6-week summer externship program for 250 underrepresented medical students, and with hands-on community-oriented clinical trial experience in underserved communities.

Application Deadline: January 28th, 2022
Read More

Leslie Warner Postdoctoral Fellowships for Cancer Research
The Fellowships will support early-stage promising trainees that are conducting innovative basic, translational, clinical, or population-based cancer research with a Yale Cancer Center member. Relevance of proposed research to our catchment area priorities is also encouraged. Candidates may have up to one year of postdoctoral experience from the time of application.

Internal Deadline: February 1, 2022
Read More
Leukemia Research Foundation Grant
The application process for the 2022-2023 funding cycle has begun! Grants of up to $100K are available to new investigators -- researchers within seven years of their first independent faculty-level position. Research projects must focus on a blood cancer (leukemia, lymphoma, myeloma, or MDS).
**Letter of Intent Due:** February 4, 2022

Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01, R21)
The purpose of this FOA is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies.
**Application Deadline:** February 5, 2022

Pediatric Oncology Student Training (POST) Program
As part of the Alex’s Lemonade Stand Foundation (ALSF), the POST Program is designed for undergraduate, graduate, and medical students who have an interest in pediatric oncology research and would like to experience the field firsthand. Students train with a pediatric oncology research mentor. Students may join a research project underway in a mentor’s lab or begin an original investigation with the mentor.
**Application Deadline:** February 21, 2022

Bladder Cancer Advocacy Network (BCAN) Early Career Investigator Awards
- **Young Investigator Award 2022:** This award is for outstanding early-career scientists and clinical cancer research investigators with a demonstrated commitment to improving the understanding and treatment of bladder cancer and/or upper tract urothelial cancer research. [https://bcan.org/wp-content/uploads/2022/01/2021_01_04_YIA-Guidelines-2022_FINAL.pdf](https://bcan.org/wp-content/uploads/2022/01/2021_01_04_YIA-Guidelines-2022_FINAL.pdf)
**Application Deadlines:** February 22, 2022

International Lung Cancer Foundation Research Grants
Adequate research funding is key to furthering developments in lung cancer treatment. Through partnering with foundations, non-profits, corporations and individual donors, the International Lung Cancer Foundation (ILCF) provides multiple funding opportunities each year to facilitate scientific advances and save lives. Before beginning your application, please review each section of this website to learn more about our available grants and our process.
**Application Deadline:** February 28, 2022

Early K99/R00 Funding Opportunity Announcements
The NCI just reissued “early K99/R00” -- NCI Pathway to Independence people w/cancer based on the latest FDA approvals & surging infections, including expertise from @SmilowCancer physicians

---

**Calendar**

*Endocrinology Clinical Dilemma*
January 21; 12:00 PM
Robert Weingold
Learn More

*Yale Cancer Answers*
January 23; 7:30 PM
NPR
*Why Do Young Women Develop Breast Cancer?*
Mariya Rozenblit, MD
Learn More

*Radiobiology and Genome Integrity Research Program*
January 24; 11:00 AM
Exploration of JAK1 as a Target Governing HNSCC Radioresistance and Development of 111In-aCD68 as a SPECT Agent for Non-invasive Tracking of Microphages In Vivo
Vanessa Kelly and Erika Belitzky
Learn More

*NCCN Patient Webinar*
January 24; 11:15 AM
Small Cell Lung Cancer
Apar Kishor P. Ganti, MD | Wendy Iverson, BSN, RN, OCN | Charles Florsheim, JD
Learn More

*Yale School of Public Health/Public Health Modeling Unit Seminar Series*
January 24; 12:00 PM
Douglas K. Owens, MD
Learn More

*Pathology in Research Progress Talk*
January 25; 9:30 AM
The NCI just reissued "early K99/R00" - NCI Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers FOAs that might be of interest to some postdoctoral fellows.
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

**Application Deadlines:** February 28, 2022

**NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)**
The purpose of this award is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions.

**Application Deadline:** February 28, 2022

**Read More**

**NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)**
This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

**Application Deadline:** February 28, 2022

**Read More**

**DeLuca Career Development Award 2022**
The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the ultimate goal to achieve independent support for their research from a national agency. For further information contact Richard.Carr@yale.edu

**Letter of Intent Due:** March 1, 2022

**Read More**

**JH Milstone Fund 2022**
This award is to support early-stage investigators and innovative research that improves understanding of bleeding, thrombosis or thrombolysis. The research can focus on the genetics, biochemistry or cell biology of coagulation or thrombolysis or on the causes, pathogenesis, diagnosis or treatment of bleeding and clotting disorders. In the absence of preliminary evidence, preliminary data are encouraged.

**Interventional Radiology Grand Rounds Lecture Series**
**January 26; 7:30 AM**
**BCLC Staging System – the 2022 Update**
Maria Reig, MD, PhD

**Learn More**

**NCCN Patient Webinar**
**January 26; 3:15 PM**
**Small Cell Lung Cancer**
Apar Kishor P. Ganti, MD | Wendy Iverson, BSN, RN, OCN | Charles Florsheim, JD

**Learn More**

**Neuroendocrine Conference**
**January 26; 4:00 PM**
**Management of Hypopituitarism**
Silvio Inzucchi, MD

**Learn More**

**Pathology Grand Rounds**
**January 27; 12:30 PM**
**Empowering Change: Effective Strategies to Improve Diversity, Inclusion and Equity in Pathology**
Marissa White, MD

**Learn More**
treatment of bleeding and clotting disorders. In the absence of preliminary data, appropriate mentors and/or collaborators are important.

**Letter of Intent Due:** March 1, 2022
Further information contact: Richard.Carr@yale.edu

### The Mark Foundation Endeavor Awards
These awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.

**Letter of Intent Due:** March 1, 2022

Read More

### Breast Cancer Alliance: Exceptional Project Grants
BCA invites clinical doctors and research scientists, including post docs, at any stage of their careers whose primary focus is breast cancer to apply for an Exceptional Project Grant. This award recognizes creative, unique, and innovative research and is open to applicants at institutions throughout the contiguous United States. Only two nominees may be put forward by YCC.

**Internal Deadline:** March 6, 2022

Read More

### BMSF Diversity in Clinical Trials Career Development Program
The intent of this program is to increase diversity in clinical trials. The initiative is comprised of a Career Development Program for early-stage clinical investigators and a Clinical Investigator Pipeline Program (BMSF CIPP) for rising second-year medical students.

**Application Deadline:** March 15, 2022

Read More

### U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers
The purpose of this FOA is to support research on human immunodeficiency virus (HIV)-associated cancers in low- and middle-income countries (LMICs) through the formation of collaborative partnerships between investigators in the United States and investigators in LMICs.

**Application Deadline:** March 30, 2022

Read More

### Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61)
The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

**Application Deadline:** April 22, 2022

Read More

### Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)
This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community.

**Application Deadline:** April 22, 2022

Read More

### Yale Pharmacology Faculty Recruitment Seminar
**January 27; 12:30 PM**
The $\sigma_2$ Receptor: From A Pharmacological Curiosity To Structure-Based Drug Discovery
Assaf Alon, PhD

Learn More

### Cancer Genetics and Prevention Seminar
**January 27; 2:30 PM**

Learn More

### Center for GI Cancers Weekly Seminar
**January 27; 4:15 PM**
*Early Phase NET Clinical Trials*
Aman Chauhan, MD

Learn More

### Endocrinology Clinical Dilemma
**January 28; 12:00 PM**
Carolina Gonzalez-Lopez

Learn More

### Yale Cancer Center Seminar
**January 28; 1:00 PM**
*Expanding Targeted Therapies in GI Cancers*
Olatunji Alese, MD, FWACS

Learn More

### Yale Cancer Answers
**January 30; 7:30 PM**
*Improving HPV-vaccine Rates among Youths*
Sangini S. Seth, MD, MPH, FACOG

Learn More

### Radiobiology and Genome Integrity Research Program
**January 31; 11:00 AM**
The Use of CRISPR-Cas9 Technology to Uncover Novel Therapeutic Targets to Enhance Meningioma Radiosensitivity
Marta Baro, PhD

Learn More

### Yale Cancer Center Grand Rounds
**February 1; 12:00 PM**
Kurt Schalper, MD, PhD and Jason Sheltzer, PhD

Learn More

### Yale Center for Immuno-Oncology Seminar (presented as part of the Human and Translational Immunology Program
Application Deadline: April 22, 2022

Read More

and Translational Immunology Program Seminar Series
February 1; 4:00 PM
Understanding Immune Responses to Cancer from Single-cell Data
Matthew Spitzer, PhD
Learn More

Neuroendocrine Conference
February 2; 4:00 PM
Pituitary Surgery: Techniques and Pitfalls
Stephanie Cheok, MD
Learn More

Pathology Grand Rounds
February 3; 12:30 PM
Pathology Quality & Safety: Managing Mistakes, Mentality and Methods
Yael Heher, MD, MPH, FRCPN (C)
Learn More

Center for GI Cancers Weekly Seminar
February 3; 4:15 PM
Industry Presentation
Serge Karpow, PharmD
Learn More

Smilow Cancer Hospital and Yale Cancer Center Clinical and Research Town Hall
February 3; 5:00 PM
Learn More

Share your news!
Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications